Get the Stockscreener App
1.10
5.98%
-0.07
After Hours:
1.07
-0.03
-2.73%
InspireMD Inc. stock is traded at $1.10, with a volume of 573.61K.
It is down -5.98% in the last 24 hours and down -28.57% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$1.17
Open:
$1.02
24h Volume:
573.61K
Relative Volume:
3.20
Market Cap:
$51.58M
Revenue:
$8.98M
Net Income/Loss:
$-48.79M
P/E Ratio:
-1.3802
EPS:
-0.797
Net Cash Flow:
$-36.77M
1W Performance:
-3.51%
1M Performance:
-28.57%
6M Performance:
-47.87%
1Y Performance:
-57.69%
1-Day Range:
$1.02
$1.1751
1-Week Range:
$1.02
$1.2647
52-Week Range:
$1.02
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.10 | 54.86M | 8.98M | -48.79M | -36.77M | -0.797 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Q1 2026 earnings preview - MSN
NSPR: CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market - TradingView
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NSPR: Q1 revenue up 122% year-over-year; U.S. relaunch expected after FDA approval in Q3 2026 - TradingView
InspireMD (NSPR) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause - Investing.com
InspireMD Inc reports results for the quarter ended March 31Earnings Summary - TradingView
InspireMD (NASDAQ:NSPR) Q1 Beat Fails to Impress as Stock Slides - ChartMill
After a recall, InspireMD says another FDA decision is due in Q3 - Stock Titan
InspireMD (NSPR) doubles Q1 revenue, details recall costs and FDA milestones - Stock Titan
InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System - marketscreener.com
InspireMD recalls CGuard Prime 135 cm carotid stent delivery system in US - Medical Buyer
InspireMD Says FDA Approved Application to Begin SwitchGuard Neuro Protection System CGUARDIANS III Study - Moomoo
FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System -- Update - Moomoo
NSPR rallies after hours on FDA green light for key stroke-prevention trial despite withdrawn annual guidance - MSN
InspireMD Recalls CGuard Prime Delivery System, Pauses U.S. Launch - TipRanks
InspireMD IncRecall Follows Technical Perf - Moomoo
InspireMD Withdraws Guidance, Recalls CGuard Prime - marketscreener.com
InspireMD receives FDA approval for stroke device study By Investing.com - Investing.com Australia
FDA lets InspireMD start pivotal study of stroke-protection device - Stock Titan
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System - The Manila Times
InspireMD receives FDA approval for stroke device study - Investing.com
InspireMD pauses U.S. launch of CGuard Prime 135 cm, withdraws 2026 revenue guidance; IDE approved for SwitchGuard TCAR study - TradingView
InspireMD Receives FDA Approval for CGUARDIANS III Pivotal Study of SwitchGuard Neuro Protection System - Quiver Quantitative
Stent launch stalls after U.S. recall; InspireMD eyes Q3 FDA nod - Stock Titan
Recall and FDA trial approval reshape InspireMD (NSPR) device outlook - Stock Titan
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System - Weekly Voice
InspireMD (NYSE:NSPR) Stock Price Up 3.5%What's Next? - MarketBeat
InspireMD recently announced that the U.S. Food and Drug Administration (FDA) has officially approved its device exemption application for the pivotal Cguardians III study on the Switchguard neuroprotection system. - Bitget
NSPR Stock Price, Quote & Chart | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
After plunging 15.2% in 4 weeks, here's why the trend might reverse for InspireMD (NSPR) - MSN
InspireMD to Announce First Quarter 2026 Financial Results - The Manila Times
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - MSN
InspireMD (NSPR) CEO Marvin Slosman reports 5.18% beneficial stake - Stock Titan
[ARS] InspireMD, Inc. SEC Filing - Stock Titan
InspireMD (NSPR) schedules 2026 shareholder meeting on director slate and share authorization - Stock Titan
InspireMD : April 2026 Investor Deck - marketscreener.com
Shareholder Lawsuit Launched Against InspireMD - National Today
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
InspireMD (NSPR) asks shareholders to approve 150M→250M share increase - Stock Titan
After Dropping 15.2% Over the Past Four Weeks, This Is Why InspireMD (NSPR) Could See a Turnaround - Bitget
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR) - Yahoo Finance
InspireMD (NYSE:NSPR) Trading Down 6.7%What's Next? - MarketBeat
Published on: 2026-04-06 18:18:37 - baoquankhu1.vn
Is InspireMD (NSPR) Stock Overpriced Now | Price at $1.49, Down 3.25%Popular Market Picks - UBND thành phố Hải Phòng
InspireMD, Inc. Enters Equity Distribution Agreement with BTIG, LLC – SEC 8-K Filing Details (April 2026) - Minichart
InspireMD Establishes New $75 Million ATM Program - TipRanks
According to the latest submitted documents, medical device company InspireMD Inc. has signed an equity distribution agreement with the sales agent. - Bitget
InspireMD Launches $75 Million At-The-Market Equity Program With BTIG - TradingView — Track All Markets
InspireMD (NSPR) sets $75M BTIG equity distribution agreement - Stock Titan
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):